Fig. 1

Patient flow and disposition. Two patients died during screening; three patients died after enrollment, all of whom received four or fewer doses of sebelipase alfa
Patient flow and disposition. Two patients died during screening; three patients died after enrollment, all of whom received four or fewer doses of sebelipase alfa